Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | CCKAR | P32238 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15645284 | 1.00 | PIK3C3 (0.46) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL13505075 | 0.88 | PTGDR2 (0.43) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL3413866 | 0.88 | PTGDR2 (0.45) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL20839913 | 0.88 | PTGDR2 (0.42) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL20839615 | 0.88 | PTGDR2 (0.42) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL4309127 | 0.87 | PTGDR2 (0.42) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL15644621 | 0.86 | PTGDR2 (0.41) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL18980291 | 0.85 | PIK3C3 (0.46) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL3417907 | 0.85 | PTGDR2 (0.41) | PIK3C3PTGDR2SRCCYP2C19RECQL | |
| SCHEMBL30135049 | 0.84 | PTGDR2 (0.48) | PIK3C3PTGDR2SRCCYP2C19CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4688771-A1 | NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2026-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | CTTN, SRC, PTK2 | PIK3C3 1915/4885PTGDR2 1918/4885SRC 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.